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Summary
 Background The electronic portal imaging device (EPID) is used for patient setup during ra-
diotherapy sessions. Dosimetric veriﬁ cation is done using ion chambers, diodes 
and thermoluminescence detectors. In intensity-modulated radiation therapy 
(IMRT) the dosimetry is a sophisticated and time-consuming task. The simulta-
neous use of amorphous silicon (aSi) detectors and the transit dosimetry (TD) 
option in the treatment planning system (TPS) (Eclipse, Varian) enables dosi-
metric pre-treatment veriﬁ cation of the IMRT plans.
 Aim The purpose of this study was to calibrate the EPID and TPS and to evaluate the 
usefulness of that method for dose veriﬁ cation in IMRT technique.
 Materials/Methods The ﬁ rst step was calibration of the aSi EPID mounted on three linear acceler-
ators (Clianc23EXS, Varian). Afterwards, conﬁ guration of the calculation algo-
rithm in TPS was carried out.
  Then dosimetric characteristics of the EPID were investigated. The EPID response 
depending on the beam mode, treatment time and static square ﬁ eld size was 
measured. The same measurements were repeated twice for three accelerators 
and analyzed.
  Additionally, three IMRT plans were treated for the pre-treatment dose evalua-
tion. The calculated dose matrix was compared with the delivered one. The sim-
ilarity of the calculated and measured ﬂ uency maps was evaluated by means of 
gamma index and score factor in Eclipse.
 Results The linearity of the EPID signal was proven. For both beam modes EPID response 
is proportional to treatment time and ﬁ eld size, within the considered ﬁ eld size 
range.
 Conclusions The gamma evaluation indicates good correlation between predicted and ac-
quired EPID image, although some differences in a high gradient area were 
found. We found the EPID-based pre-treatment IMRT veriﬁ cation method to be 
a good quality assurance (QA) procedure. Quite frequent control of the meth-
od and periodic recalibration of the used device are required.
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BACKGROUND
The quality assurance (QA) procedure in radio-
therapy generally demands dose measurement 
as well as patient positioning check. In conven-
tional techniques the dosimetric veriﬁ cation is 
based on well-tried methods carried out mostly 
during treatment sessions. For that, ion cham-
bers, diodes or thermoluminescence detectors 
are routinely used. At the same time, the elec-
tronic portal imaging device (EPID) used on 
the accelerator is utilized for visualization and 
patient setup check. Another approach is re-
quired for IMRT delivery. Mostly plan veriﬁ ca-
tion is made in the phantom before real patient 
irradiation [1–4]. The complexity of IMRT plans 
and non-uniform dose distribution caused a new 
effective and reliable form of plan veriﬁ cation to 
be sought. In order to achieve that the applica-
tion of EPID was extended [5–7]. Additionally, 
the implementation of new amorphous silicon 
(aSi) detectors and transit dosimetry (TD) in 
the treatment planning system (TPS) allowed 
veriﬁ cation methods to be developed. Due to 
both tools working together there is a possibili-
ty to predict dose matrix and to detect dose ma-
trix delivered during irradiation. There are an 
increasing number of publications on aSi EPID 
detectors and their dosimetry applications. The 
literature reports good digital image quality, 
shorter exposure time and dosimetric proper-
ties of aSi EPID [8–18].
In this study, ﬁ rst the calibration problems of 
the method with regard to different kinds of de-
vice components are described. Also the dosi-
metric features of the detector, such as linearity, 
ﬁ eld size dependence, accuracy and reproduci-
bility discussed in the literature were investigat-
ed [8,12,13,16,17].
Finally, the last part of the study focuses on IMRT 
plan veriﬁ cation. A ﬁ rst clinical application is dis-
cussed. Examples of three selected plans with a 
dynamic multileaf collimator (dMLC) are used 
to demonstrate the facility of the method.
Contemporary commercially available software 
enables comprehensive analysis of the acquired 
data. So, the predicted dose represented by a cal-
culated ﬂ uency map can be quantitatively com-
pared with the corresponding acquired dose – 
real ﬂ uency map. Dose evaluation can be made 
by dose matrix comparison with isodose deline-
ation, point dose and proﬁ le measurements or 
gamma index calculation [19,20]. Individual cri-
teria for plan evaluation can be deﬁ ned depend-
ing on the clinical case.
AIM
The aim of the present study was to calibrate the 
aSiEPID devices and TPS calculation algorithm 
for IMRT dose prediction and measurement. The 
second aim was to evaluate dosimetric properties 
of aSiEPID and the usefulness of that method for 
dose veriﬁ cation in IMRT technique.
MATERIALS AND METHODS
Dosimetric tools calibration
The EPID system consists of an image detector 
unit (IDU), image acquisition system (IAS) and 
PortalVision workstation. The IAS electronics 
and interface read out and store data from the 
IDU. The IDU is an array of photodiodes with a 
scintillating layer above [8,21].
Calibration was executed for EPID type aS500, 
two types of IAS: IAS2 and IAS3, and two types of 
mechanical portal imager arms: RArm and EArm. 
The following three device sets were tested:
• A: Clinac23EXS-IAS2-aS500-RArm,
• B: Clinac23EXS-IAS2-aS500-EArm,
• C: Clinac23EXS-IAS3-aS500-EArm.
The machine named “A” is equipped with an 80-
leaf dMLC while “B” and “C” are 120-leaf dMLC 
machines.
Within the calibration process a mechanical 
cassette adjustment due to the isocenter of the 
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accelerator was done. Next image calibration 
was performed. As part of that, the dark ﬁ eld 
and ﬂ ood ﬁ eld had to be taken and beam pro-
ﬁ le correction of the signal was made. The next 
step was conﬁ guration of a calculation algorithm 
for dose prediction. In order to do that, the se-
quence of measurements and calculations pre-
cisely determined by the manufacturer was made 
[8,21]. As a result of the calibration the predict-
ed and measured ﬂ uency map can be expressed 
in calibrated units (CU).
The essentials of EPID-based dosimetry are the 
accuracy of the imager calibration and the cal-
culation algorithm. Any inaccuracy in that proc-
ess could lead to inconsistency between the pre-
dicted and measured dose.
Linearity of response
The measurements of dose response were per-
formed for two photon beam energy modes, 6MV 
and 20MV, at source-portal surface distance (SSD) 
of 105cm. This distance is recommended by the 
manufacturer. The portal cassette was irradiated 
with 7 ﬁ eld sizes, 3×3cm, 5×5cm, 7×7cm, 10×10cm, 
15×15cm, 20×20cm, 30×30cm, with different mon-
itor units (MU): 2, 3, 4, 5, 8, 10, 50, 100, 150 200, 
250, 300MU. The clinical routine accelerator 
mode 300MU/min was set up. Accelerator mode 
corresponds to dose rate deﬁ ned in reference con-
ditions. With the following parameters the dose 
rate of 1Gy/min is represented: 300MU/min ac-
celerator mode, at 5cm depth, 10cm square ﬁ eld 
size and SSD of 100cm. The same measurements 
were performed three times with the same con-
ditions on three machines. The data obtained in 
this manner were collected and the mean value 
of the EPID signal was calculated.
Field size dependence
For the second test, the dependence of the por-
tal dose as a function of ﬁ eld size was evaluat-
ed. The applied SSD and dose rate were 105cm 
and 300MU/min respectively. Again both pho-
ton beam energies and three accelerators were 
investigated. A square ﬁ eld size ranging from 
3×3cm to 30×30cm was tested. Measurements in 
the range of 2 to 300 MU were performed. Mean 
detector readouts for 6MV and 20MV for all ma-
chines were also calculated.
The stability of the imaging device and repro-
ducibility were evaluated when the above test 
was made. The linearity and ﬁ eld size depend-
ence were assessed over three sessions during 4 
months.
Portal dose prediction
Pre-treatment veriﬁ cation was performed in 15 
head and neck cancer patients. For all of them 
two kinds of plans were evaluated: large ﬁ elds and 
boost. In order to assess these treatment plans, 
the delivered dose distribution was compared to 
that predicted by the TPS. For presentation 3 cas-
es were used. In the ﬁ rst patient 14 large ﬁ elds 
and 6 boost ﬁ elds were assessed, in the second 
patient 14 and 8, while in the third patient 10 
and 6 ﬁ elds respectively were analyzed.
In these measurements, the detector was posi-
tioned at SSD=105cm. The data were acquired 
at 0° gantry position and 0° collimator posi-
tion. The dose rate used in measurements was 
300MU/min.
The accuracy of delivered ﬂ uency maps versus 
those generated in TPS was assessed by mean of 
gamma index and score calculated in TPS too. 
The score is an overall result of gamma evaluation 
of the image. The criteria of gamma evaluation 
(dose difference of 3% and distance-to-agreement 
(DTA) of 2mm) were set on the basis of clinical 
experience and publication data [2,8,19,20,]. In 
the literature, one can mostly ﬁ nd values of 3% 
and 3mm respectively. In the present study, a low-
er value of 2mm was used to provide even more 
restrictive plan evaluation, which is demanded in 
IMRT techniques. Additionally the overall score 
considering whole portal image pixels was tak-
en into assessment.
RESULTS
Linearity of response
Figure 1 shows the average EPID signal as a func-
tion of irradiation time measured for machine 
“B”. The linear response was observed over the 
measured irradiation time range from 2 to 300MU 
for three tested accelerators. The methodologi-
cal error is ±0.001CU. For presentation, only re-
sults measured for 3×3cm, 10×10cm and 30×30cm 
were chosen. The same linearity was observed for 
the other analyzed ﬁ elds.
Higher uncertainties in the measured signals 
were found for the bigger ﬁ eld sizes rather than 
for the small ﬁ elds and more for shorter irradia-
tion times than for long ones. The highest error 
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value of 9.0% was achieved at 20MV on machine 
“B”. For the others the error is lower: 6.7% for 
machine “A” and 8.3% for machine “C”. In this 
work the highest maximal error value over three 
sessions of 9% for machine “B” was established as 
the measurements error for all machines.
In parallel, in the course of these tests the independ-
ence of beam energy was proven. This is consistent 
with results reported in the literature [8,16].
Field size dependence
The ﬁ eld size dependence is given in Figure 2. 
The results for machine “B” were chosen for 
presentation. For illustration data obtained for 
100MU were selected. The EPID signal is propor-
tional to ﬁ eld size within the considered ﬁ eld size 
range from 3×3cm to 30×30 cm. These results can 
be observed for both analyzed energies.
Analogically to signal linearity, when compar-
ing the ﬁ eld size dependence over three meas-
urements, discrepancies of about 9.0% were 
found.
The extensional functions were ﬁ tted to the meas-
ured data. The mean ﬁ t index (R2) is over 0.986 
for all evaluated energies and accelerators.
Portal dose prediction
308 ﬁ elds (30 treatment plans, 2 plans per pa-
tient) for 15 head and neck cases were evaluat-
ed. The obtained data were grouped into two 
categories: large ﬁ elds and boost. Average gam-
ma index and the overall image score were ana-
lyzed. The analysis was based on the criterion of 
both 3% dose difference and 2mm distance differ-
ence. Good results are represented by low value 
of average gamma (close to zero value) and high 
value of score (close to unity). For each case the 
mean values of average gamma index and score 
were calculated in two categories. For presenta-
tion three patients were chosen. The obtained 
results of a dosimetry evaluation for 6 treatment 
plans are given in Table 1. This table contains 
only mentioned mean values. Table 1 generally 
shows good agreement between measured and 
calculated dose distribution found in both cate-
gories. The data achieved for the large ﬁ elds sug-
gest that in all cases the correspondence between 
delivered and predicted dose is slightly worse in 
that category than in boost. The mean gamma 
values in large ﬁ elds are within the range of 0.212 
to 0.484. In the boost category, mean gamma val-
ues ﬂ uctuate between 0.084 and 0.273.
The best result over 15 patients was achieved in 
the boost category. It is 0.084. The corresponding 
mean score value is 0.998. The highest obtained 
mean gamma value is 0.484 in large ﬁ elds. It cor-
responds with a mean score value of 0.961.
DISCUSSION
Since the ﬁ rst use of the ﬂ at panel detector, in-
creased use of the amorphous silicon EPID as a 
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Figure 1. EPID response – function of dose for diff erent square fi eld 
sizes, averaged for three measurements performed for machine “B”. 
Data acquired at 6MV. Data acquired at 20MV represent the same 
values in the range of measurement error 9%. CU – calibration 
unit, MU – monitor unit.
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Figure 2. EPID response – function of fi eld size. Measurements 
performed on machine “B” for irradiation time 100MU, averaged 
over three sessions. Data acquired at 6MV. Data acquired at 20MV 
represent the same values in the range of measurement error 9%. 
CU – calibration unit, MU – monitor unit.
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dosimetric tool is reported. Nowadays it is obvi-
ous that aSi-based EPID has not only good fea-
tures serving portal imaging but also IMRT ver-
iﬁ cation.
The similarity between the results of our work 
and those from previous publications has been 
shown [8,12,13,16,17]. In the present study the 
data demonstrate that the signal response is lin-
ear with exposure time and proportional to open 
ﬁ eld size. It should be emphasized that the meas-
urements show similar behaviour for different 
energy modes – results do not depend on pho-
ton energy. Moreover, the presented results do 
not deviate signiﬁ cantly for accelerators that are 
equipped with almost identical yet different im-
aging devices. However, the maximal measure-
ment deviation of about 9% was detected in the 
course of three sessions with several-week inter-
vals. In another publications lower detector re-
producibility (e.g. 1%, 2% or 4%) was reported 
[8–10]. This suggests that frequent and consci-
entious dosimetric calibration is required.
IMRT plans can be evaluated with the help of 
portal dosimetry. Considering the results of pre-
treatment plan veriﬁ cation we conclude that the 
obtained dose differences are dependent on ﬁ eld 
size category. The large ﬁ eld treatment plans were 
clearly treated with higher uncertainty than small 
ﬁ elds. This may be caused by the fact that there 
are local high gradient spots more often than in 
boost. Some authors emphasize that maximum 
error increases linearly with leaf speed [17].
With the aim of daily IMRT plans control im-
provement, the mean values of average gamma 
and score index were calculated for each ﬁ eld cat-
egory. More advanced statistical methods will be 
used in subsequent works which are under prep-
aration. The present study shows the ﬁ rst results 
and preliminary analysis after a short time of ex-
perience with the system. In future, with a growing 
number of veriﬁ ed plans, clear criteria for IMRT 
plan acceptance should be established.
In this work the pre-treatment plan veriﬁ cation 
procedure is described. This method is carried 
out before patient treatment sessions. Nowadays 
in vivo EPID dosimetry is possible too. However, 
it is not universally applied in radiotherapy. It 
requires the implementation of advanced calcu-
lation programs, considering patient tissue den-
sities, involving problems of geometry, patient 
thickness, etc [3]. In the Centre of Oncology in 
Gliwice such kind of in vivo dosimetry is being 
worked on. Meanwhile, the pre-treatment veri-
ﬁ cation method is performed.
A potential limitation of EPID dosimetry is the 
limited size of the ﬂ at panel and lengthy dura-
tion of the process [9].
CONCLUSIONS
The general conclusion can be drawn that aSi-
based EPID and transit dosimetry option of TPS 
is appropriate for static and dynamic dose meas-
urements. For the future, the development of a 
viable clinical strategy for application of this new 
veriﬁ cation method is necessary.
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